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Breast cancer is the most common malignancy to affect women in
North America and Europe. An estimated 5 000 000 women will be
diagnosed with the disease in the next decade (Gelber et al, 1993).
A number of endocrine options are available for the treatment of
breast cancer (Howell et al, 1996; Howell and Dowsett, 1997);
currently, tamoxifen is the most widely used endocrine agent, with
the new generation aromatase inhibitors being increasingly used in
post-menopausal women (Buzdar et al, 1996, 1997). Tamoxifen
acts primarily as an anti-oestrogen, competing with oestrogen at
oestrogen-receptor binding sites in tissues such as the breast.
Tamoxifen is used for both the treatment of early and advanced
disease. Aromatase inhibitors work by inhibiting aromatase, the
enzyme which catalyses the conversion of androgens (androstene-
dione and testosterone) to oestrogens (oestrone and oestradiol) in a
process known as aromatization. In post-menopausal women,
oestrogens are mostly derived from adrenal androgens through this
conversion.
From the different and complementary modes of action of these
two approaches, it is possible that using both in combination may
provide a more effective method of treating breast cancer in post-
menopausal women. A study is currently being carried out in which
tamoxifen is compared with the aromatase inhibitor anastrozole
(Arimidex), and the combination of tamoxifen plus anastrozole in
post-menopausal women with early breast cancer is also being
investigated.
Anastrozole is a potent, selective, non-steroidal aromatase
inhibitor belonging to the triazole class. Preclinical pharmacolog-
ical studies show that anastrozole is a potent inhibitor of placental
aromatase, and is selective for the aromatase enzyme complex
without affecting the other cytochrome P-450 enzymes involved in
the synthesis of adrenal glucocorticoid and mineralocorticoid
hormones (Dukes et al, 1996). Anastrozole has been shown to be a
well-tolerated (Buzdar et al, 1996) and selective aromatase
inhibitor in post-menopausal women (Yates et al, 1996). Doses of
anastrozole up to 10 mg once daily do not affect cortisol or aldos-
terone secretion by the adrenal gland (Plourde et al, 1994). At
doses of 1 mg and 10 mg once daily, anastrozole leads to potent
inhibition of aromatase (96.7% and 98.1%, respectively, expressed
as the geometric mean), and suppresses plasma oestrogens to the
limit of detection of available assays (Geisler et al, 1996). Plasma
levels of oestrone, oestradiol and oestrone sulphate were
suppressed by ³86.5%, ³83.5% and ³93.5% irrespective of dose.
Anastrozole has been compared with megestrol acetate in large
randomized trials in post-menopausal women with advanced
breast cancer (Buzdar et al, 1996). A recent survival update based
on the combined data from these studies (31-month follow-up)
showed that treatment with 1 mg anastrozole results in signifi-
cantly longer survival compared with 160 mg megestrol acetate
(Buzdar et al, 1997).
At present, the anti-oestrogen tamoxifen is the endocrine agent
of choice as adjuvant therapy for breast cancer in post-menopausal
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Royal Marsden Hospital, London SW3 6JJ, UKwomen. To investigate whether or not the use of tamoxifen in
combination with anastrozole provides more effective drug
therapy for post-menopausal women with early breast cancer, a
large clinical trial has been undertaken. Before initiating this large
clinical trial programme comparing anastrozole, tamoxifen and the
combination of the two drugs in post-menopausal women with
early breast cancer, it was necessary to determine whether anastro-
zole had any effect on tamoxifen blood levels, and hence on the
clinical efficacy of tamoxifen. It is noteworthy that the prototype
aromatase inhibitor aminoglutethimide led to an approximate
halving of plasma levels of tamoxifen (Lien et al, 1990).
A pharmacokinetic trial was, therefore, carried out to assess the
following end points: (1) the effect of anastrozole on the pharma-
cokinetics of tamoxifen; (2) the safety and tolerability of the
combination of anastrozole and tamoxifen therapy; (3) the effect
of tamoxifen on the action of anastrozole, with respect to oestra-
diol suppression. This paper reports the findings of this trial.
PATIENTS, MATERIALS AND METHODS
Patient demography
Thirty-four post-menopausal women with early breast cancer who
had received 20 mg tamoxifen once daily as adjuvant therapy for
at least 10 weeks were recruited from three centres in the UK.
Post-menopausal women were defined as those aged 50 years or
over who had not menstruated in the last 12 months, or women of
any age with follicle stimulating hormone (FSH) levels greater
than 40 IU l–1. One patient was removed from the study because
she was found to be premenopausal.
Exclusion criteria included: premenopausal women or drug-
induced menopause; levels of aspartate aminotransferase, alanine
aminotransferase, or total bilirubin more than three times the upper
limit of the reference range; other abnormal laboratory test results
at baseline that would place the patient at risk or confound the
results of the trial; and concurrent therapy with a non-approved or
experimental drug, or with drugs that might affect steroid hormone
status and/or tamoxifen steady-state levels.
The demographic characteristics of all randomized patients are
summarized in Table 1. Chemotherapy had previously been given to
one patient in the anastrozole group, and six patients in the placebo
group. Thirteen patients in the anastrozole group, and 14 patients in
the placebo group had previously received radiotherapy. At baseline,
the two groups were balanced with respect to demographic variables.
The trial was designed and monitored to comply with the ethical
principles of Good Clinical Practice (GCP), and in accordance
with the Declaration of Helsinki. All patients included in the trial
had given their written informed consent.
Study design
The trial was a randomized, double-blind, parallel-group, multi-
centre trial. All patients had been taking 20 mg tamoxifen for at
least 10 weeks. All patients continued to take 20 mg tamoxifen
orally once a day throughout the trial, and, in addition, were
randomized to receive either 1 mg anastrozole (16 patients) or
matching placebo (18 patients) once daily on a double-blind basis.
Randomized treatment started on day 0 and ended on day 28. To
assess any post-treatment effects of the combination therapy of
anastrozole and tamoxifen, all patients were required to continue
taking tamoxifen alone for another 14 days (day 42).
Blood samples were taken from each patient at days –7 and 0 for
baseline measurements; days 14 and 28 for on-treatment measure-
ments, and day 42 for post-treatment measurements. Tamoxifen
and anastrozole/placebo tablets were taken together at the same
time each day so that blood samples could be taken at trough drug
levels.
Key assessments
Serum levels of tamoxifen were analysed according to the high-
performance liquid chromatography method described by
Johnston et al (1993). Overall, recovery varied from 79% to 93%
and was corrected for by the internal recovery control. The
intra-assay coefficient of variation was 2.2% at a mean level of
135 ng ml–1. The sensitivity limit was <5 ng ml–1. Plasma levels of
anastrozole were determined using a validated method involving
solvent extraction, capillary gas chromatography, and separation
with electron capture detection (ECD).
Serum levels of oestradiol were determined using a method
previously reported (Dowsett et al, 1987). Because of variability
of baseline oestradiol concentrations among individuals, oestra-
diol values were expressed as the oestradiol proportion, defined as
the geometric mean of the levels of oestradiol measured during
treatment (days 14 and 28) divided by the geometric mean of the
levels of oestradiol measured at baseline (days –7 and 0). Any
oestradiol values that lay below the limit of quantification were
substituted by the value assigned as the limit of quantification
(3 pmol l–1).
Tolerability and safety assessments
An adverse event was defined as any detrimental change in a
patient’s condition during the study. All adverse events were
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Table 1 Patient demographics
Demographic characteristics Anastrozole (1 mg) Placebo
Number of patients exposed 16 18
Age (years)
n 16 18
Median 64.0 61.0
Minimum 51 42
Maximum 81 73
Height (cm)
n 15 18
Median 162.0 165.0
Minimum 152.0 150.0
Maximum 178.0 172.0
Weight (kg)
n 15 18
Median 73.0 71.5
Minimum 56.9 53.3
Maximum 92.1 100.8
Origin (number of patients)
Caucasian 16 17
Afro-Caribbean 0 1
The height and weight of one patient in the anastrozole group were not
taken.recorded, irrespective of whether or not the event was considered
to be related to the trial therapy. Any clinically significant
abnormal laboratory results recorded at any time were reported as
adverse events. Biochemical and haematological variables were
monitored throughout the trial to assess drug safety.
Statistical analyses
The primary end points of this trial were serum tamoxifen levels
and oestradiol proportion, with the treatment comparison of
interest being that of anastrozole with placebo.
The comparison of the serum tamoxifen levels between the two
groups was performed by analysis of covariance (ANCOVA). The
two groups were compared with respect to the ‘on-treatment’
tamoxifen level. The ‘on-treatment’ value was derived by taking
the geometric mean of the day 14 and day 28 tamoxifen concentra-
tions. The estimate of the difference in ‘on-treatment’ tamoxifen
levels between the two groups was derived by taking the differ-
ence in the least square mean values obtained from the ANCOVA.
The comparison of the oestradiol levels was performed in a
similar way to the analysis of tamoxifen levels, the methods
differed only by the derivation of the end point for analysis. The
analysis of oestradiol levels considered the ‘oestradiol proportion’.
The ‘oestradiol proportion’ was defined as the ‘on treatment’
oestradiol level divided by the ‘baseline’ oestradiol level, with ‘on
treatment’ and ‘baseline’ defined as above.
RESULTS
Serum concentrations of tamoxifen
The serum tamoxifen concentrations (means±standard deviation)
during the trial are summarized in Table 2. As the data followed a
normal distribution, relevant arithmetic descriptive statistics are
given. In both patient groups, the steady-state tamoxifen concen-
trations remained similar both before and during co-administration
of 20 mg tamoxifen and either 1 mg anastrozole or placebo. A
difference was seen in the baseline levels of tamoxifen between
the anastrozole and placebo groups. However, when the data were
adjusted for baseline, there was no significant difference in tamox-
ifen concentrations between these two groups during treatment
(P = 0.919) (Figure 1). There was no significant difference
(P = 0.953) in tamoxifen concentrations between the anastrozole
and placebo groups during the post-treatment period, as measured
on day 42 (Figure 1). Therefore, co-administration of 1 mg anas-
trozole and 20 mg tamoxifen did not significantly affect the
steady-state serum concentrations of tamoxifen.
Serum concentrations of oestradiol
In patients taking placebo in the presence of tamoxifen, the serum
oestradiol concentrations on days 14 and 28 were similar to base-
line concentrations (days –7 and 0) and post-treatment (day 42)
concentrations when tamoxifen was taken alone (Figure 2). The
serum concentrations of oestradiol on days 14 and 28 in patients
taking anastrozole in the presence of tamoxifen were markedly
decreased compared with baseline concentrations. There was a
significant difference (P < 0.0001) for the on-trial treatment
oestradiol proportion, adjusted for baseline, between the anastro-
zole and placebo groups.
Plasma concentrations of anastrozole
The mean plasma concentrations of anastrozole measured on days
14 and 28, when patients were taking the combination of tamoxifen
and anastrozole, were 33.2±10.2 ng ml–1 and 33.9 ± 12.0 ng ml–1
respectively.
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Table 2 Serum tamoxifen concentrations during co-administration of 20 mg
tamoxifen and either 1 mg anastrozole or placebo
Tamoxifen concentration (ng ml–1)
Day –7 0 14 28 42
Anastrozole group
n 15 15 15 15 15
Mean 171.0 154.8 156.8 153.1 160.6
Standard deviation 76.8 71.7 66.0 72.9 73.1
Placebo group
n 18 18 18 18 18
Mean 123.8 116.4 121.7 117.1 123.4
Standard deviation 54.9 46.4 40.3 45.0 50.3
One patient was removed from the study because she was found to be
premenopausal.
Baseline 14 28 42
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Figure 1 The mean tamoxifen proportion relative to baseline geometric
mean by treatment group
Figure 2 Mean oestradiol serum concentration (±s.e.) during treatment for
28 days with 20 mg tamoxifen and either 1 mg anastrozole daily or placeboTolerability and safety evaluation
A total of 18 patients (52.9%) experienced adverse events during
the trial. In the anastrozole group, nine patients experienced a total
of 25 adverse events whereas, in the placebo group, nine patients
experienced a total of 28 adverse events. Overall, the incidence of
adverse events in the two groups was similar, 56.3% of patients
treated with anastrozole (1 mg) and 50% of patients treated with
placebo reporting at least one adverse event.
Hot flushes were experienced by four patients, all of whom were
taking tamoxifen and placebo. Digestive disorders comprising diar-
rhoea, nausea and vomiting were experienced by five patients in the
anastrozole group and one patient in the placebo group. Of the five
patients in the anastrozole group, two patients experienced diar-
rhoea, two patients experienced nausea, and one patient experienced
vomiting. The patient in the placebo group experienced nausea.
There was one withdrawal due to adverse events (from the
placebo group) and one serious adverse event (dental pain, which
occurred in the anastrozole group); the latter was reported before
treatment commenced. No deaths were reported during the study.
No apparent differences were seen between either treatment
group or within each group with respect to pre- and post-treatment
haematology and biochemistry measurements.
DISCUSSION
Before initiating the adjuvant breast cancer trial comparing anastro-
zole with tamoxifen and the combination of anastrozole plus
tamoxifen in post-menopausal women, it was important to investi-
gate whether the combination of the two drugs had any effect upon
plasma tamoxifen levels because any reduction in tamoxifen could,
in theory, affect the clinical efficacy of tamoxifen. This study was
appropriate because in earlier studies of the prototype aromatase
inhibitor aminoglutethimide, in combination with tamoxifen,
aminoglutethimide showed an interaction with tamoxifen which
led to a 50% reduction in plasma levels of the anti-oestrogen (Lien
et al, 1990). The combination of aminoglutethimide and tamoxifen
has been compared clinically with tamoxifen alone in post-
menopausal women with advanced breast cancer (Milstead et al,
1985; Ingle et al, 1986; Rose et al, 1986; Smith et al, 1986); in none
of these studies was there a significant enhancement of efficacy
with the combination. It may be speculated that this might be due in
part to the lower tamoxifen levels with combined therapy.
Tamoxifen is extensively metabolized by cytochrome P-450-
dependent hepatic mixed function oxidase (Jacolot et al, 1991) and
aminoglutethimide is a powerful cytochrome P-450 inducer.
Anastrozole is more selective than aminoglutethimide, and a
weak inducer of cytochrome P-450, with patterns of induced
enzymes dissimilar to aminoglutethimide. Co-administration of
anastrozole with a variety of compounds, for example antipyrine,
cimetidine and warfarin, indicate that anastrozole is unlikely to
result in clinically significant drug interactions mediated by
cytochrome P-450 (Dowsett et al, 1998). Nonetheless, in vivo
pharmacokinetic interactions are not always predictable. Thus, a
pilot clinical study before the large adjuvant trial was considered
prudent.
The results of this study confirmed that serum tamoxifen concen-
trations were unaffected by the presence of anastrozole, as shown
by the unchanged serum tamoxifen concentrations compared both
with the placebo group and with the post-treatment period in which
tamoxifen alone was given to all patients. A difference in baseline
serum concentrations of tamoxifen was observed between the anas-
trozole and placebo groups. This is consistent with the considerable
inter-patient variability in tamoxifen concentrations previously
reported in studies involving post-menopausal women with
advanced breast cancer (Patterson et al, 1980; Bratherton et al,
1984; Frenay et al, 1994). The difference in baseline serum concen-
trations of tamoxifen is very unlikely to have affected the results of
the study, because the longitudinal design with a parallel placebo
group allowed the on-treatment values to be adjusted for baseline.
The results of this trial also confirmed that oestradiol concentra-
tions were suppressed in patients given a combination of anastro-
zole plus tamoxifen for a period of 28 days. The levels of
suppression seen in this study were highly comparable to those
seen in a study in which anastrozole was taken alone (Geisler et al,
1996). Because there was not an anastrozole alone arm or treat-
ment period in this current trial, it is not possible to exclude a
minor effect of tamoxifen on the action of anastrozole; however,
these data clearly demonstrate that anastrozole remains a very
effective suppressant of oestradiol in the presence of tamoxifen.
The plasma levels of anastrozole obtained in this trial of patients
with early breast cancer were informally compared with those from
two other clinical trials in which advanced breast cancer patients
received 1 mg anastrozole once daily for 60 weeks, but in which
anastrozole levels were taken at day 28 (n = 95) (Zeneca, data on
file) or for 28 days (n = 10) (Geisler et al, 1996). Steady-state
concentrations of anastrozole in patients taking 1 mg anastrozole in
these trials ranged from approximately 9.0 to 108.0 ng ml–1 and
from 22.0 to 83.9 ng ml–1, respectively, and in the present trial from
22.0 to 60.0 ng ml–1 on day 14 and 14.0 to 66.0 ng ml–1 on day 28.
The mean concentration of anastrozole was 39.0±14.7 ng ml–1 in
the 60-week trial (n = 95), 37.7 ng ml–1 in the 28-day trial (n = 10),
and 33.2±10.2 ng ml–1 on day 14 and 33.9±12.0 ng ml–1 on day 28
of the combination trial. Although definitive conclusions as to
whether or not tamoxifen affects anastrozole blood levels cannot be
made, studies are in progress specifically to examine this question.
It is important to note, however, that if such an interaction exists
between tamoxifen and anastrozole, it is clearly insufficient to
reduce the oestrogen-suppressive effects of anastrozole.
The combination of tamoxifen plus anastrozole treatment was well
tolerated during the study. No unexpected adverse events were
related to the use of combination therapy, and no significant differ-
ence in adverse events was reported between the anastrozole and
placebo groups. These data are supportive of the use of the combina-
tion of tamoxifen plus anastrozole in the long-term adjuvant setting.
In conclusion, the results of the present study confirm that anas-
trozole did not affect the pharmacokinetics of tamoxifen when the
two drugs were given in combination to post-menopausal women
with early breast cancer. Thus, in the on-going adjuvant trial, one
can be assured that for patients randomized to combined therapy,
full-dose tamoxifen will be received. In addition, the oestradiol
suppressant effects of anastrozole appear to be unaffected by
tamoxifen. If tamoxifen has any effect on anastrozole blood levels,
such an interaction is clearly insufficient to reduce the oestradiol
suppressive effects of anastrozole.
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